ПОВОЛЖСКИЙ ОНКОЛОГИЧЕСКИЙ ВЕСТНИК 1( 28)’ 2017
23. Ljungberg B. et al. Tumour vascular endothelial growth factor( VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma // Urological research.— 2003.— Vol. 31, № 5.— P. 335-340.
24. Maroto P., Rini B. Molecular biomarkers in advanced renal cell carcinoma // Clinical Cancer Research.— 2014.— Vol. 20, № 8.— P. 2060-2071.
25. Moch H. An overview of renal cell cancer: pathology and genetics // Seminars in cancer biology.— Academic Press, 2013.— Vol. 23, № 1.— P. 3-9.
26. Moch H. et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma // Cancer.— 2000.— Vol. 89, № 3.— P. 604-614.
27. Motzer R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma // New England Journal of Medicine.— 2007.— Vol. 356, № 2.— P. 115-124.
28. Nisman B. et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy // Urology.— 2010.— Vol. 76, № 2.— P. 513. e1-513. e6.
29. Rini B. I. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma // Journal of Clinical Oncology.— 2008.— Vol. 26, № 22.— P. 3743-3748.
30. Sachdeva K. et al. Renal Cell Carcinoma [ Электронный ресурс ]. URL: http:// emedicine. medscape. com / article / 281340-overview. Дата обращения: 02.08.16
31. Shinagare A. B. et al. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer
Genome Atlas – Renal Cell Carcinoma( TCGA – RCC) Imaging Research Group // Abdominal imaging.— 2015.— Vol. 40, № 6.— P. 1684-1692.
32. Teloken P. E. et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma // The Journal of urology.— 2009.— Vol. 182, № 5.— P. 2132-2136.
33. Varga Z. et al. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker? // Urological research.— 2002.— Vol. 30, № 2.— P. 122-125.
34. von Teichman A. et al. VHL mutations and dysregulation of pVHL-and PTEN-controlled pathways in multilocular cystic renal cell carcinoma // Modern Pathology.— 2011.— Vol. 24, № 4.— P. 571-578.
35. Wader J. V. et al. Chromophobe Renal Cell Carcinoma // Online Journal of Health and Allied Sciences.— 2013.— Vol. 12, № 1( 15).
36. Ward C. S. et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy // Cancer research.— 2010.— Vol. 70, № 4.— P. 1296-1305.
37. Zurita A. J. et al. A cytokine and angiogenic factor( CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma // Annals of oncology.— 2011.— С. mdr047.
38. Zurita-Saavedra A. et al. Multivariate analysis of cytokines and angiogenic factors( cafs) and established prognostic parameters in metastatic renal cell carcinoma( mrcc) patients( pts) receiving pazopanib or placebo // Annals of oncology.— Great Clarendon st, Oxford ox2 6dp, England: Oxford Univ Press, 2012.— Vol. 23.— P. 261-261.
С. Ю. Иливанов и соавт. Рациональное использование биомаркеров в диагностике рака почки в клинической практике 79